Page 93 - JCTR-11-2

Journal of Clinical and

Translational Research

SPECIAL ISSUE ARTICLE
Clinical applications of a novel, Food and Drug

Administration -approved biomimetic matrix in
refractory diabetic foot ulcers: An observational

case series analysis

1,2
Sara Rose-Sauld 1,2 , Jennifer Skolnik 1,2 , and Adam Landsman *
1 Department of Orthopaedic Surgery, Division of Foot and Ankle Surgery, Massachusetts General
Hospital, Boston, Massachusetts, United States of America
2 Department of Orthopaedics, Foot and Ankle Research and Innovation Lab (FARIL), Boston,
Massachusetts, United States of America
(This article belongs to the Special Issue: Innovations in Wound Healing)

Abstract

Background: Biomimetic matrix (BMM) is a fully synthetic matrix composed of
*Corresponding author: self-assembling peptides, an emerging class of biomaterials, for the treatment of
Adam Landsman chronic wounds. Aim: This preliminary case series explores the potential clinical
(alandsman@mgh.harvard.edu)
applications of BMM in eight patients with chronic diabetic foot ulcers. The patients
Citation: Rose-Sauld S, Skolnik J, were selected based on wound chronicity and a lack of response to standard of care
Landsman A. Clinical applications and/or previous treatments with biologics, including amniotic-derived materials,
of a novel, food and drug
administration -approved biomimetic decellularized collagen, and living cell/collagen-derived products. Results: A total
matrix in refractory diabetic foot of eight subjects were evaluated and monitored in this case series. All subjects had
ulcers: An observational case diabetes, and the comorbidities included venous stasis, Charcot neuroarthropathy,
series analysis. J Clin Transl Res.
2025;11(2):87-93. obesity, osteomyelitis, peripheral vascular disease, and a history of prior partial
doi: 10.36922/jctr.24.00063 foot amputation. All subjects treated with BMM responded after one to three
Received: September 19, 2024 applications. Overall, treatment with BMM resulted in an average percent wound
area reduction of 63.6% over 6 weeks for chronic wounds that had remained open
1st revised: November 11, 2024
for an average of 21.5 months. Conclusion: BMM treatment reduced the wound
2nd revised: January 13, 2025 area and depth of complex, stalled chronic diabetic lower extremity wounds.
Accepted: March 27, 2025 Relevance for patients: BMM, a synthetic self-assembling peptide-based matrix,
demonstrated progression in treating stalled diabetic wounds that were not
Published online: April 18, 2025
responsive to human- or animal-derived products.
Copyright: © 2025 Author(s).
This is an open-access article
distributed under the terms of the Keywords: Diabetic foot ulcer; Biomimetic matrix; Synthetic self-assembling peptide;
Creative Commons AttributionNon-
Commercial 4.0 International (CC Wound healing
BY-NC 4.0), which permits all
non-commercial use, distribution,
and reproduction in any medium,
provided the original work is
properly cited. 1. Introduction
Publisher’s Note: AccScience Chronic wounds represent a significant challenge in clinical practice, particularly when
Publishing remains neutral with traditional therapies fail to induce healing. Advanced therapies for chronic wounds
1
regard to jurisdictional claims in
published maps and institutional typically include the application of advanced wound dressings or tissue-harvested/
affiliations. engineered skin substitutes to reduce inflammation and accelerate the healing process,

Volume 11 Issue 2 (2025) 87 doi: 10.36922/jctr.24.00063